AbSci's SoluPro™ Expression Platform
Efficient, cost-effective protein production is essential to the economic viability of protein and antibody based products. These proteins are primarily produced using eukaryotic systems, which have long development cycles, fermentation processes lasting 2-3 weeks, and use costly reagents. Long-term viability of these novel biologic therapies depends on access to an expression system that rapidly produces high quality, properly folded, active protein that can be seamlessly scaled-up.
AbSci has developed a proprietary genetically engineered E. coli-based expression system, SoluPro™, which bypasses inclusion body formation, and achieves soluble expression of full-length antibodies, antibody fragments, and a diverse range of other recombinant proteins. AbSci’s next-generation SoluPro™ system eliminates the formation of inclusion bodies in the production process, allowing high quality, soluble versions of these highly valued proteins and antibodies to be produced in quantity.
How SoluPro™ works:
The AbSci solution utilizes the simplest, best studied, most genetically accessible, and least expensive expression organism, E. coli. Our approach utilizes metabolic and genetic engineering to achieve tightly regulated expression using multiple carbon source inducers. This tightly regulated control over expression is combined with a host strain exhibiting an oxidizing cytoplasm, which enables production of soluble, properly folded protein in gram per liter quantities. The result is an expression platform that combines short production cycles of 1-2 days with high soluble yields, making an ideal platform for both discovery and manufacturing.
The core of our technology is SoluPro™’s ability to homogeneously and independently control induction off of multiple carbon source promoters without suffering from catabolite repression. This homogeneous induction is achieved not only at a population scale, but also within each and every cell. SoluPro™ is therefore able to slow down production rates, and enable the cells to produce properly folded, non-aggregated protein.
Expression in an oxidizing cytoplasm offers a number of advantages over secretion to the periplasm:
Short production cycles of only 1-2 days (compared to 3-5 days)
No limits on protein size, which is constrained by the secretion machinery
Large capacity of the cytoplasm enables high soluble yields compared to the periplasm
These characteristics enable a broad range of protein products to be produced using a single host-plasmid combination. This all-in-one platform is an ideal tool for use during the discovery phase, enabling the production of lab scale protein for screening in a matter of days. Importantly, the system also scales for manufacturing, which eliminates the extended cell line development processes normally associated with eukaryotic systems.